Aclarion Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives
OrthoSpineNews
MARCH 31, 2025
Over $20M raised in Q1 with nearly $15M cash on hand No debt, no preferred equity, and no warrants with strike prices near the current market Nasdaq compliant: fully meets bid price and shareholder equity requirements Pivotal CLARITY trial fully funded with initial interim results expected in Q2 2026 BROOMFIELD, Colo.,
52 
Let's personalize your content